Evaluation and Treatment of Patients with Major Depressive Disorder: Are We Considering All the Options?

Megan Maroney, PharmD
Published Online: Wednesday, August 22, 2012
Follow Pharmacy_Times:
This activity is supported by an educational grant from Mylan Specialty, LP.
 
Evaluation and Treatment of Patients with Major Depressive Disorder: Are We Considering All the Options?
 
Megan Maroney, PharmD

Clinical Assistant Professor
Ernest Mario School of Pharmacy
Rutgers University
Piscataway, New Jersey
Clinical Psychiatric Pharmacist
Monmouth Medical Center
Long Branch, New Jersey

 

 
Megan Maroney, PharmD, has no financial relationships with commercial interests to disclose related to this activity.
 
Pharmacy Times Office of Continuing Professional Education Planning Staff
 
Judy V. Lum, MPA, Ann C. Lichti, CCMEP, and Elena Beyzarov, PharmD, have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
Pharmacy Times Editorial Staff
 
Jennifer Whartenby and David Allikas have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
The peer reviewer of this activity has no relevant financial relationships with commercial interests to disclose related to this activity.
 

 
Educational Objectives
 
Upon completion of this educational activity, participants should be able to:
  1. Review the pathophysiology and epidemiology of major depressive disorder (MDD), atypical depression, and treatment-resistant depression.
  2. Address challenges of treating depression, including safety concerns (eg, adverse effects, drug–food interactions), noncompliance, relapse, and inadequate response to antidepressant therapy.
  3. Discuss current and emerging antidepressant treatments, including strategies used for typical and treatment-resistant depression.
  4. Formulate counseling strategies to improve patient outcomes in depression.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: August 10, 2012
Expiration date: August 10, 2014
Estimated time to complete activity: 2 hours
Fee: This lesson is free online
 
Click here to view this activity.

Related Articles
Comorbid anxiety disorders compound challenges associated with bipolar disorder treatment.
Although believed to be distinct, different psychiatric disorders may produce similar loss of gray matter in the brain.
There is greater need for comprehensive medication management (CMM) delivered by board-certified psychiatric pharmacists on the health care team.
Rapid cycling bipolar disorder occurs in up to 20% of bipolar patients, but it is difficult to treat.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$